Fas-FasL interactions modulate host defense against systemic Candida albicans infection

Journal of Infectious Diseases

Volumn 180, Issue 5, 1999, Pages 1648-1655

  Netea, Mihai G ^a   Van Der Meer, Jos W M ^a   Meis, Jacques F G M ^a   Kullberg, Bart Jan ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; FAS ANTIGEN; FAS LIGAND; INTERLEUKIN 1; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; HOST RESISTANCE; HUMORAL IMMUNITY; IMMUNE STATUS; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIGENS, CD95; CANDIDA ALBICANS; CANDIDIASIS; FAS LIGAND PROTEIN; HUMANS; INTERLEUKIN-1; KIDNEY; MACROPHAGES, PERITONEAL; MEMBRANE GLYCOPROTEINS; MICE; NEUTROPHILS; PHAGOCYTOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032752274     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315058     Document Type: Article

References (35)

1. 1. Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 1994; 76: 959-62.
2. 2. Itoh N, Yonehara S, Ishii A, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66: 233-43.
3. 3. Watanabe-Fukunaga RC, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992; 356:314-7.
4. 4. Cohen PL, Eisenberg RA, Lpr and gld single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 1991; 9:243.
5. 5. Lemay S, Mao C, Singh AK. Cytokine gene expression in the MRL/lpr model of lupus nephritis. Kidney Int 1996; 50:85-93.
6. 6. Huang FP, Feng GJ, Lindop G, Stott DI, Liew FY. The role of interleukin-12 and nitric oxide in the development of spontaneous autoimmune disease in MRL lpr/lpr mice. J Exp Med 1996; 183:1447-54.
7. 7. Conceicao-Silva F, Hahne M, Schroter M, Louis J, Tschopp J. The resolution of lesions induced by Leishmania major in mice requires a functional Fas (Apo-1, CD95) pathway of cytotoxicity. Eur J Immunol 1998; 28:237-45.
8. 8. Huang FP, Xu D, Esfandiari EO, Sands W, Wei XQ, Liew FY. Mice defective in Fas are highly susceptible to Leishmania major infection despite elevated IL-12 synthesis, strong Th1 responses, and enhanced nitric oxide production. J Immunol 1998: 160:4143-7.
9. 9. Jensen ER, Glass AA, Clark WR, Wing EJ, Miller JF, Gregory SH. Fas (CD95)-dependent cell-mediated immunity to Listeria monocytogenes. Infect Immun 1998; 66:4143-50.
10. 10. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994; 331:1325-30.
11. 11. Kullberg BJ. Trends in immunotherapy of fungal infections. Eur J Clin Microbiol Infect Dis 1997; 16:51-5.
12. 12. Van 't Wout JW, Van der Meer JWM, Barza M, Dinarello CA. Protection of neutropenic mice from lethal Candida albicans infection by recombinant interleukin 1. Eur J Immunol 1988; 18:1143-6.
13. 13. Steinshamn S, Waage A. Tumor necrosis factor and interleukin-6 in Candida albicans infection in normal and granulocytopenic mice. Infect Immun 1992; 60:4003-8.
14. 14. Netea MG, Blok WL, Kullberg BJ, et al. Pharmacological inhibitors of tumor necrosis factor production exert differential effects in lethal endotoxemia and in infection with live microorganisms in mice. J Infect Dis 1995; 171: 393-9.
15. 15. Mencacci A, Cenci E, Del Sero G, et al. Defective co-stimulation and impaired Th1 development in tumor necrosis factor/lymphotoxin-alpha double-deficient mice infected with Candida albicans. Int Immunol 1998; 10: 37-48.
16. 16. Steinshamn S, Bemelmans MHA, Van Tits LHJ, Bergh K, Buurman WA, Waage A. TNF receptors in murine Candida albicans infection. Evidence for an important role of TNF receptor p55 in antifungal defense. J Immunol 1996; 157:2155-9.
17. 17. Netea MG, Van Tits LJH, Curfs JHAJ, et al. Increased susceptibility of TNFαLTα double knockout mice to systemic candidiasis through impaired recruitment of neutrophils and phagocytosis of Candida albicans. J Immunol 1999; 163:1498-505.
18. 18. Netea MG, Demacker PNM, Kullberg BJ, et al. Low-density-lipoprotein receptor deficient mice are protected against lethal endotoxinemia and severe gram-negative infections. J Clin Invest 1996; 97:1366-72.
19. 19. Lehrer RI, Cline MJ. Interactions of Candida albicans with human leukocytes and serum. J Bacteriol 1969; 98:996-1004.
20. 20. Kullberg BJ, Van 't Wout JW, Van Furth R. Role of granulocytes in enhanced host resistance to Candida albicans induced by recombinant interleukin-1. Infect Immun 1990; 58:3319-24.
21. 21. Kullberg BJ, Van 't Wout JW, Van Furth R. No effect of recombinant human interleukin-1 on the numbers of peripheral blood and peritoneal leukocytes during an acute inflammation. Inflammation 1991; 15:457-70.
22. 22. Kullberg BJ, Van 't Wout JW, Hoogstraten C, Van Furth R. Recombinant interferon-γ enhances resistance to acute disseminated Candida albicans infection in mice. J Infect Dis 1993; 168:436-43.
23. 23. Van 't Wout JW, Linde I, Leijh PCJ, Van Furth R. Contribution of granulocytes and monocytes to resistance against experimental disseminated Candida albicans infections. Eur J Clin Microbiol Infect Dis 1988; 7: 736-41.
24. 24. Djeu JY, Blanchard DK, Halkias D, Friedman H. Growth inhibition of Candida albicans by human polymorphonuclear neutrophils: activation by interferon-γ and tumor necrosis factor. J Immunol 1986; 137:2980-4.
25. 25. Fuse Y, Nishimura H, Maeda K, Yoshikai Y. CD95 (Fas) may control the expansion of the activated t cells after elimination of bacteria in murine listeriosis. Infect Immun 1997; 65:1883-91.
26. 26. Hahn H, Kaufmann SH. The role of cell-mediated immunity in bacterial infections. Rev Infect Dis 1981; 3:1221-50.
27. 27. Marino MW, Dunn A, Grail D, et al. Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci USA 1997; 94:8093-8.
28. 28. Kullberg BJ, Netea MJ, Curfs JHAJ, Keuter M, Meis JFGM, Van der Meer JWM. Recombinant murine granulocyte colony-stimulating factor protects against acute disseminated Candida albicans infection in non-neutropenic mice. J Infect Dis 1998; 177:175-81.
29. 29. Lo HJ, Kohler JR, DiDomenico B, Loebenberg D, Cacciapuoti A, Fink GR. Nonfilamentous C. albicans mutants are avirulent. Cell 1997; 90:939-49.
30. 30. Romani L, Mencaci A, Cenci E, et al. Neutrophil production of IL-12 and IL-10 in candidiasis and efficacy of IL-12 therapy in neutropenic mice. J Immunol 1997; 158:5349-56.
31. 31. Sala M, Walsh K. TNF alpha regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation. Nat Med 1998; 4:415-20.
32. 32. Liles WC, Kiener PA, Ledbetter JA, Aruffo A, Klebanoff SJ. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J Exp Med 1996; 184:429-40.
33. 33. Heummann D, Le Roy D, Zanetti G, et al. Contribution of TNF/TNF receptor and of Fas ligand to toxicity in murine models of endotoxemia and bacterial peritonitis. J Inflamm 1995-96; 47:173-9.
34. 34. Edwards CK, Zhou T, Zhang J. et al. Inhibition of superantigen-induced proinflammatory cytokine production and inflammatory arthritis in MRL-lpr/lpr mice by a transcriptional inhibitor of TNF-alpha. J Immunol 1996; 157:1758-72.
35. 35. Lynch DH, Alderson MR, Ramsdell F. Immunoregulatory effects of Fas-mediated signalling. J Cell Biochem 1996; 60:39-46.